CL
CLGN
Occupied territories Halal Trading Room controversy review flags companies domiciled in Israel under Occupied territories. as of 2026-09-11.
A public record of federal contracting, not a Sharia ruling and not our assessment of this company. It sits beside the verdict above and changes nothing about it.
Methodology breakdown computing — it will appear here on its own.
CollPlant Biotechnologies Ltd. (CLGN) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for CLGN — this runs off the critical path so the page paints first. It will appear here on its own.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2025-12-31. CLGN files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
AAOIFI Fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 441.14% | 30.00% | Fail |
| Interest-bearing investments | 866.62% | 30.00% | Fail |
| Non-permissible income | 16.03% | 5.00% | Fail |
Usmani Fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.39% | 33.00% | Pass |
| Interest-bearing investments | 51.84% | 33.00% | Fail |
| Non-liquid assets | 48.15% | at least 20.00% | Pass |
| Non-permissible income | 16.03% | 5.00% | Fail |
MSCI Fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 26.39% | 33.33% | Pass |
| Cash + interest-bearing securities | 51.84% | 33.33% | Fail |
| Accounts receivable | 51.85% | 33.33% | Fail |
| Non-permissible income | 16.03% | 5.00% | Fail |
FTSE Fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass |
| Cash + interest-bearing securities | 51.84% | 33.33% | Fail |
| Accounts receivable | 51.85% | 50.00% | Fail |
| Non-permissible income | 16.03% | 5.00% | Fail |
Dow Jones Islamic Market Fail
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 81.29% | 33.00% | Fail |
| Cash + interest-bearing securities | 159.70% | 33.00% | Fail |
| Accounts receivable | 0.03% | 33.00% | Pass |
| Non-permissible income | 16.03% | 5.00% | Fail |
S&P Shariah Fail
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 54.06% | 33.00% | Fail |
| Cash + interest-bearing securities | 106.21% | 49.00% | Fail |
| Accounts receivable | 0.02% | 49.00% | Pass |
| Non-permissible income | 16.03% | 5.00% | Fail |
MSCI M-Series Fail
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 54.06% | 33.33% | Fail |
| Cash + interest-bearing securities | 106.21% | 33.33% | Fail |
| Accounts receivable | 106.23% | 49.00% | Fail |
| Non-permissible income | 16.03% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 54.40 | NEUTRAL |
| Stochastic %K (14) | 12.93 | BUY |
| CCI (20) | 25.58 | NEUTRAL |
| Williams %R (14) | -87.07 | BUY |
| MACD (12,26,9) | 0.03 | BUY |
| ROC (10) | 14.94 | BUY |
| Momentum (10) | 0.46 | BUY |
| EMA (10) | 3.46 | BUY |
| SMA (10) | 3.50 | BUY |
| EMA (20) | 3.38 | BUY |
| SMA (20) | 3.32 | BUY |
| EMA (30) | 3.35 | BUY |
| SMA (30) | 3.24 | BUY |
| EMA (50) | 3.43 | BUY |
| SMA (50) | 3.32 | BUY |
| EMA (100) | 4.45 | SELL |
| SMA (100) | 3.58 | SELL |
| EMA (200) | 8.94 | SELL |
| SMA (200) | 7.53 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About CollPlant Biotechnologies Ltd.
Healthcare · Biotechnology
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 43 |
| ⏰ 4H | BEARISH | 29 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.